diethylnitrosamine has been researched along with perindopril in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukui, H; Ikenaka, Y; Imazu, H; Kuriyama, S; Nakatani, T; Noguchi, R; Tsujinoue, H; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
| Hamed, O; Kazem, A; Nasr, M; Selima, E | 1 |
| Abdelghany, RH; El-Ahwany, E; Goda, R; Helal, NS; Mahmoud, AAA; Saber, S | 1 |
3 other study(ies) available for diethylnitrosamine and perindopril
| Article | Year |
|---|---|
Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats.
Topics: Alkylating Agents; Angiotensin-Converting Enzyme Inhibitors; Animals; Choline; Diethylnitrosamine; Disease Models, Animal; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Perindopril; Precancerous Conditions; Rats; Rats, Inbred F344; Renin-Angiotensin System | 2002 |
Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Antirheumatic Agents; Carcinogens; Carcinoma, Hepatocellular; Curcumin; Diethylnitrosamine; Drug Therapy, Combination; Hypoxia-Inducible Factor 1, alpha Subunit; Isoxazoles; Leflunomide; Liver; Liver Neoplasms; Male; Mice; Neovascularization, Pathologic; Perindopril; Platelet Endothelial Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2014 |
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Fosinopril; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Perindopril; Phenylurea Compounds; Phosphorylation; Renin-Angiotensin System; Signal Transduction; Sorafenib; Time Factors; Transcription Factor RelA; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2018 |